After 2nd Bet on Familiar Drug, Impact Bio Lands $1B Celgene Buyout
Xconomy
JANUARY 7, 2018
More is in the offing if Impact’s drug fedratinib passes a series of regulatory and sales hurdles. Morgan week—the annual healthcare investment gathering in San Francisco—with a blockbuster deal, acquiring privately-held Impact Biomedicines for $1.1 billion upfront in cash.
Let's personalize your content